المؤلفون: Christian Jackisch, Seock-Ah Im, Michelino De Laurentiis, Jean-Yves Pierga, Mahesh Shivhare, Ramon Colomer, Kyung Hae Jung, Tanja Badovinac Crnjevic, Alexandra Hogea, Daniil Stroyakovskii, Sarah Heeson, Antoinette R. Tan, Zbigniew Nowecki, André Mattar, Whitney P. Kirschbrown, Christian Schem, Eleonora Restuccia

المساهمون: Tan, A. R., Im, S. -A., Mattar, A., Colomer, R., Stroyakovskii, D., Nowecki, Z., De Laurentiis, M., Pierga, J. -Y., Jung, K. H., Schem, C., Hogea, A., Badovinac Crnjevic, T., Heeson, S., Shivhare, M., Kirschbrown, W. P., Restuccia, E., Jackisch, C.

المصدر: The Lancet. Oncology. 22(1)

مصطلحات موضوعية: 0301 basic medicine, Adult, medicine.medical_specialty, Time Factors, Receptor, ErbB-2, medicine.medical_treatment, Injections, Subcutaneous, Population, Phases of clinical research, Hyaluronoglucosaminidase, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Loading dose, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Trastuzumab, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Biomarkers, Tumor, Humans, education, Neoadjuvant therapy, Neoplasm Staging, education.field_of_study, business.industry, Middle Aged, medicine.disease, Chemotherapy regimen, Neoadjuvant Therapy, 030104 developmental biology, Treatment Outcome, Oncology, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Pertuzumab, business, Febrile neutropenia, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99e575a2761394ec388f6b5a6dee91bfTest
https://pubmed.ncbi.nlm.nih.gov/33539750Test

المؤلفون: Haiying Liu, Sanne de Haas, Seock-Ah Im, Francisco J. Esteva, Jigna Shah, Sherene Loi, Monika Patre, C. Lambertini, Sung Bae Kim, Yifan Wang, Mark Beresford, Aruna Mani, Leisha A. Emens, Roberto Salgado, Cristina Saura, Michelino De Laurentiis

المساهمون: Emens, L. A., Esteva, F. J., Beresford, M., Saura, C., De Laurentiis, M., Kim, S. -B., Im, S. -A., Wang, Y., Salgado, R., Mani, A., Shah, J., Lambertini, C., Liu, H., de Haas, S. L., Patre, M., Loi, S.

المصدر: The Lancet. Oncology. 21(10)

مصطلحات موضوعية: 0301 basic medicine, Male, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Receptor, ErbB-2, Population, Programmed Cell Death 1 Receptor, Phases of clinical research, Breast Neoplasms, Placebo, Ado-Trastuzumab Emtansine, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Antineoplastic Agents, Immunological, Double-Blind Method, Atezolizumab, Trastuzumab, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Medicine, Humans, education, Adverse effect, education.field_of_study, business.industry, Middle Aged, medicine.disease, Metastatic breast cancer, Survival Analysis, 030104 developmental biology, Treatment Outcome, Oncology, chemistry, Trastuzumab emtansine, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6df8ea55582f078b15ed0a54a5bdc723Test
https://pubmed.ncbi.nlm.nih.gov/33002436Test